Management of Hashimoto's Thyroiditis with Immune-Mediated Recurrent Pregnancy Loss
Primary Recommendation
Optimize thyroid function with levothyroxine to achieve TSH ≤ 2.5 mIU/L before conception and throughout pregnancy; prednisone plus aspirin is NOT recommended for this indication based on the highest quality evidence showing no benefit and significant maternal harm. 1, 2
Pre-Conception Thyroid Optimization (Essential First Step)
The cornerstone of management is aggressive thyroid optimization, not immunosuppression:
Check TSH and free T4 immediately to verify adequacy of current levothyroxine dosing, as inadequately treated hypothyroidism is strongly associated with recurrent pregnancy loss. 1
Target TSH ≤ 2.5 mIU/L pre-conception and confirm this level on at least two separate occasions 4–6 weeks apart before attempting pregnancy. 1
Test for thyroid peroxidase antibodies (anti-TPO) because thyroid autoimmunity increases the risk of miscarriage, preterm delivery, and progression of hypothyroidism during pregnancy. 1
Adjust levothyroxine dose as needed to achieve target TSH; the Endocrine Society recommends dose adjustment in all women with known hypothyroidism who are planning conception. 1
Early Pregnancy Thyroid Management
Increase levothyroxine by approximately 30% (≈ two extra tablets per week) immediately upon pregnancy confirmation without awaiting laboratory results, because thyroid hormone requirements rise by 4–6 weeks gestation. 1
Measure TSH every 4 weeks and maintain TSH < 2.5 mIU/L in the first trimester and < 3.0 mIU/L in the second and third trimesters. 1
Instruct the patient to contact her clinician promptly after a missed period to reassess TSH and adjust levothyroxine, since untreated or under-treated hypothyroidism is linked to fetal loss, impaired neurodevelopment, preterm birth, and low birth weight. 1
Why NOT Prednisone Plus Aspirin
The evidence against this combination is compelling:
A landmark randomized controlled trial of 202 women with autoantibodies and recurrent fetal loss showed prednisone (0.5–0.8 mg/kg/day) plus aspirin (100 mg/day) did NOT improve live birth rates compared to placebo (65% vs. 56%, P=0.19). 2
Prednisone plus aspirin significantly increased prematurity (62% vs. 12%, P<0.001), maternal hypertension (13% vs. 5%, P=0.05), and maternal diabetes (15% vs. 5%, P=0.02). 2
A 2022 study of euthyroid women with thyroid autoimmunity undergoing IVF showed prednisone (10 mg/day) plus aspirin (100 mg/day) did NOT improve clinical pregnancy rates (57.5% vs. 63.5%, P=0.414) or live birth rates (49.6% vs. 47.3%, P=0.762). 3
The American Society for Reproductive Immunology 2025 guidelines emphasize that immunomodulatory treatments are often provided to unselected patients without appropriate investigation of underlying etiologies. 4
Progesterone Supplementation
The role of progesterone is more nuanced:
Vaginal micronized progesterone may be considered for women with a history of recurrent pregnancy loss, as suggested by some guidelines (American Society for Reproductive Medicine, German/Austrian/Swiss Society). 5
One randomized trial showed combination therapy including progesterone achieved 85% live births in women with idiopathic recurrent miscarriage, though this study combined progesterone with prednisone and aspirin (making it difficult to isolate progesterone's effect). 6
FDA labeling indicates progesterone capsules are used for secondary amenorrhea and endometrial support, with dosing typically 200–400 mg daily. 7
If used, initiate vaginal micronized progesterone 200–400 mg daily starting after ovulation or embryo transfer and continue through the first trimester if pregnancy is achieved. 7, 6
Low-Dose Aspirin
Low-dose aspirin (81–100 mg daily) may be considered in select cases, particularly if there is concurrent antiphospholipid syndrome (which requires formal testing with lupus anticoagulant and anticardiolipin antibodies). 5
For isolated Hashimoto's thyroiditis without antiphospholipid antibodies, aspirin alone has no proven benefit for recurrent pregnancy loss prevention. 2, 3
Alternative Immunomodulation (Emerging Evidence)
Intravenous immunoglobulin (IVIG) showed promise in a 2025 study for Hashimoto's disease or isolated anti-thyroid antibodies in pregnancy, with significantly improved live births (OR = 4.6,95% CI 1.1–18.1) without adverse effects. 8
IVIG targets the autoimmune mechanism directly rather than using non-specific immunosuppression, though this approach requires further validation and is not yet standard of care. 8
Recommended Regimen for Your Patient
For a woman with Hashimoto's thyroiditis and immune-mediated recurrent pregnancy loss:
Levothyroxine optimization to TSH ≤ 2.5 mIU/L pre-conception (mandatory). 1
Increase levothyroxine by 30% immediately upon pregnancy confirmation (mandatory). 1
Consider vaginal micronized progesterone 200–400 mg daily starting after ovulation/embryo transfer through first trimester (optional, some guideline support). 7, 5
Do NOT use prednisone plus aspirin due to lack of efficacy and significant maternal/fetal harm. 2, 3
Consider low-dose aspirin 81 mg daily ONLY if antiphospholipid antibodies are documented (requires formal testing). 5
Monitor TSH every 4 weeks during pregnancy and adjust levothyroxine to maintain first-trimester TSH < 2.5 mIU/L. 1
Critical Pitfalls to Avoid
Do NOT assume current levothyroxine dose is adequate without recent TSH verification; many patients with primary hypothyroidism remain undertreated. 1
Do NOT delay thyroid optimization while pursuing other interventions; inadequate thyroid hormone replacement is a modifiable cause of recurrent pregnancy loss. 1
Do NOT apply non-pregnant TSH reference ranges during gestation; pregnancy-specific targets (first trimester < 2.5 mIU/L, second/third trimester < 3.0 mIU/L) are mandatory. 1
Do NOT use prednisone based on outdated protocols; the highest quality randomized trial definitively showed harm without benefit. 2
Do NOT prescribe immunosuppression without documented immune pathology beyond thyroid autoimmunity alone. 4